Highlights of This Issue 2721

SPECIAL FEATURES

CCR Translations

2723
Metformin and Pancreatic Cancer: A Clue Requiring Investigation
Michael Pollak
See article p. 2905

Molecular Pathways

2726
Molecular Pathways: Vasculogenic Mimicry in Tumor Cells: Diagnostic and Therapeutic Implications
Dawn A. Kirschmann, Elisabeth A. Seftor, Katharine M. Hardy, Richard E.B. Seftor, and Mary J.C. Hendrix

CCR Focus

2734
Progress in Pediatric Cancer
Susan E. Bates

2735
Genetically InFormed Therapies—A "GIFT" for Children with Cancer
Carol J. Thieue and Susan L. Cohn

2740
Promising Therapeutic Targets in Neuroblastoma
Katherine K. Matthey, Rani E. George, and Alice L. Yu

2754
Advances in the Genetics of High-Risk Childhood B-Progenitor Acute Lymphoblastic Leukemia and Juvenile Myelomonocytic Leukemia: Implications for Therapy
Mignon L. Loh and Charles G. Mullighan

2768
Epigenetic Changes in Pediatric Solid Tumors: Promising New Targets
Elizabeth R. Lawlor and Carol J. Thieue

2780
The Future Is Now: Chimeric Antigen Receptors as New Targeted Therapies for Childhood Cancer
Daniel W. Lee, David M. Barrett, Crystal Mackall, Rimas Orentas, and Stephan A. Grupp

2791
Using Germline Genomics to Individualize Pediatric Cancer Treatments
Navin Pinto, Susan L. Cohn, and M. Eileen Dolan

Perspective

2801
Disrupting the Networks of Cancer
Daniel F. Camacho and Kenneth J. Pienta

Review

2809
Pharmacogenomics in Early-Phase Oncology Clinical Trials: Is There a Sweet Spot in Phase II?
Peter H. O'Donnell and Walter M. Stadler

HUMAN CANCER BIOLOGY

2817
Suppression of Skeletal Muscle Turnover in Cancer Cachexia: Evidence from the Transcriptome in Sequential Human Muscle Biopsies

MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma
Molecular Profiling of Pancreatic Neuroendocrine Tumors in Sporadic and Von Hippel-Lindau Patients
Daniela Speisky, Aurélie Duces, Vinciane Rebour, Pascal Hammel, Alain Sauvanet, Stéphane Richard, Pierre Bedossa, Michel Vidaud, Arnaud Murat, Patricia Niccoli, Jean-Yves Scoazec, Philippe Ruszniewski, and Anne Couvelard for the GTE Group (Groupe d’Étude des Tumeurs Endocrines)

CANCER THERAPY: CLINICAL
Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer
Navid Sadeghi, James L. Abbuzzese, Sai-Ching J. Yeung, Manal Hassan, and Donghui Li
See commentary p. 2723

Pharmacokinetics and Repolarization Effects of Intravenous and Transdermal Granisetron
Jay W. Mason, Daniel S. Selness, Thomas E. Moon, Bridget O’Mahony, Peter Donachie, and Julian Howell

Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience
Jennifer Wheleter, Apostolia M. Tsimbiridou, David Hong, Aung Naing, Gerald Falchook, Sarina Piha-Paul, Siqing Fu, Stacy Moulder, Betzzy Stephen, Sijin Wen, and Razelle Kurzrock

IMAGING, DIAGNOSIS, PROGNOSIS
Tumor Infiltrating Immune Cells and Outcome of Merkel Cell Carcinoma: A Population-Based Study
Harri Sihto, Tom Böehling, Heli Kavola, Virve Koljonen, Marko Salmi, Sirpa Jalkanen, and Heikki Joensuu

Global Methylation Profiling for Risk Prediction of Prostate Cancer
Saswati Mahapatra, Eric W. Klee, Charles Y.F. Young, Zhifu Sun, Rafael E. Jimenez, George G. Klee, Donald J. Tindall, and Krishna Vanaja Donkena

Correlation of ERG Expression and DNA Methylation Biomarkers with Adverse Clinicopathologic Features of Prostate Cancer
Ken Kron, Liyang Liu, Dominique Trudel, Vajayanti Pethe, John Trachtenberg, Neil Fleshner, Bharati Bapat, and Theodoros van der Kwast
Gender Influences the Class III and V β-Tubulin Ability to Predict Poor Outcome in Colorectal Cancer

Marisa Mariani, Gian Franco Zannoni, Stefano Sioletic, Steven Sieber, Candice Martino, Enrica Martinelli, Claudio Coco, Giovanni Scambia, Shohre Shahabi, and Cristiano Ferlini

An Apoptosis Methylation Prognostic Signature for Early Lung Cancer in the IFCT-0002 Trial

Florence de Fraipont, Guénaële Levallet, Christian Creveuil, Emmanuel Bergot, Michèle Beau-Faller, Mounia Mounawar, Nicolas Richard, Martine Antoine, Isabelle Rouquette, Marie-Christine Favrot, Didier Debieuvre, Denis Braun, Virginie Westeel, Elisabeth Quoix, Elisabeth Brambilla, Pierre Hainaut, Denis Moro-Sibilot, Franck Morin, Bernard Milleron, and Gérard Zalcman on behalf of the Intergroupe Francophone de Cancérologie Thoracique (IFCT)

Prognostic and Predictive Role of JWA and XRCC1 Expressions in Gastric Cancer

Shouyu Wang, Xuming Wu, Yansu Chen, Jianbing Zhang, Jingjing Ding, Yan Zhou, Song He, Yongfei Tan, Fulin Qiang, Jin Bai, Jinyan Zeng, Zhenghua Gong, Aiping Li, Gang Li, Oluf Dimitri Roe, and Jianwei Zhou

ABOUT THE COVER

Methylation of the tumor suppressor gene Ras association domain family 1A (RASSF1A) is an independent adverse prognostic factor in patients with early-stage non–small cell lung carcinoma treated in the phase III trial on perioperative chemotherapy, IFCT-0002. The cover image is a photomicrograph showing RASSF1A protein distribution in immortalized interphasic bronchial epithelial cells, HBEC3, using confocal microscopy. RASSF1A is stained in red (Alexa-fluo red-labeled secondary antibody). Nuclei are shown in light purple (DAPI). For details, see the article by de Fraipont and colleagues on page 2976 of this issue.